Fig_7.tif (2.35 MB)
Representative axial images of the investigated human colon carcinoma xenografts including tumor morphology (T2w images, top row), tumor perfusion parameter maps (middle row) and 18F-FDG-PET (bottom row) before therapy (left column) and after a one-week treatment course of regorafenib (right column). Note the significant decrease of tumor plasma flow (mL/100mL/min) and tumor glucose metabolism (TTB) after regorafenib therapy between baseline and follow-up.
figure
posted on 2015-02-10, 03:04 authored by Ralf S. Eschbach, Wolfgang P. Fendler, Philipp M. Kazmierczak, Marcus Hacker, Axel Rominger, Janette Carlsen, Heidrun Hirner-Eppeneder, Jessica Schuster, Matthias Moser, Lukas Havla, Moritz J. Schneider, Michael Ingrisch, Lukas Spaeth, Maximilian F. Reiser, Konstantin Nikolaou, Clemens C. CyranThe hyperintense central tumor regions on the T2-weighted image after therapy are consistent with increasing, therapy-induced tumor necrosis.
History
Usage metrics
Categories
Keywords
colorectal adenocarcinomasmonitoring regorafenib therapy effectstumor cell proliferationhtpsMethodsHuman colorectal adenocarcinoma xenograftspfTTBimagingperfusion MRI parametersregorafenib therapy effectstumor microvascular densityImmunohistochemical Validation ObjectivesTomlki7 control groupmultimodalmultiparametricMonitoring Regorafenib Therapy10 therapy groupimmunohistochemicalpvday 7. ImmunohistochemistrycorrelationExperimental Colon Carcinomas
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC